Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Teaching Rounds | 14 | 2024 | 276 | 5.100 |
Why?
|
Antidepressive Agents, Second-Generation | 3 | 2018 | 489 | 1.120 |
Why?
|
Primary Prevention | 4 | 2022 | 1185 | 0.980 |
Why?
|
Diverticulitis | 1 | 2023 | 185 | 0.710 |
Why?
|
Practice Guidelines as Topic | 11 | 2023 | 7390 | 0.630 |
Why?
|
Cannabinoids | 1 | 2021 | 172 | 0.620 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2024 | 2252 | 0.610 |
Why?
|
Aspirin | 2 | 2021 | 3127 | 0.600 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2021 | 2746 | 0.590 |
Why?
|
Patient Selection | 2 | 2020 | 4237 | 0.580 |
Why?
|
Dementia | 2 | 2023 | 2686 | 0.570 |
Why?
|
Diabetic Neuropathies | 1 | 2021 | 405 | 0.560 |
Why?
|
Gout Suppressants | 1 | 2018 | 177 | 0.560 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 3196 | 0.540 |
Why?
|
Clostridium Infections | 1 | 2023 | 557 | 0.540 |
Why?
|
Gynecological Examination | 1 | 2015 | 30 | 0.510 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2024 | 2197 | 0.500 |
Why?
|
Hot Flashes | 1 | 2018 | 330 | 0.490 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2018 | 396 | 0.480 |
Why?
|
Estrogen Replacement Therapy | 2 | 2018 | 1208 | 0.470 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3245 | 0.460 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1878 | 0.450 |
Why?
|
Anemia, Sickle Cell | 1 | 2022 | 1061 | 0.440 |
Why?
|
Menopause | 2 | 2018 | 1645 | 0.420 |
Why?
|
Atherosclerosis | 2 | 2021 | 3400 | 0.420 |
Why?
|
Thyroxine | 1 | 2016 | 666 | 0.410 |
Why?
|
Hypercholesterolemia | 2 | 2017 | 1141 | 0.400 |
Why?
|
Gout | 1 | 2018 | 621 | 0.380 |
Why?
|
Cardiovascular Diseases | 4 | 2022 | 15498 | 0.380 |
Why?
|
Mass Screening | 6 | 2023 | 5425 | 0.370 |
Why?
|
Hypothyroidism | 1 | 2016 | 668 | 0.370 |
Why?
|
Risk Assessment | 11 | 2022 | 23974 | 0.370 |
Why?
|
Hypoglycemic Agents | 2 | 2024 | 3085 | 0.370 |
Why?
|
Bone Density Conservation Agents | 1 | 2018 | 794 | 0.360 |
Why?
|
Hormone Replacement Therapy | 1 | 2016 | 751 | 0.360 |
Why?
|
Prostate-Specific Antigen | 1 | 2019 | 2465 | 0.330 |
Why?
|
Depressive Disorder | 2 | 2017 | 3735 | 0.330 |
Why?
|
Guideline Adherence | 2 | 2019 | 2218 | 0.330 |
Why?
|
Inpatients | 1 | 2020 | 2545 | 0.310 |
Why?
|
Anti-HIV Agents | 1 | 2024 | 4524 | 0.300 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2024 | 12143 | 0.300 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1866 | 0.280 |
Why?
|
Israel | 2 | 2018 | 716 | 0.260 |
Why?
|
Breast Neoplasms | 8 | 2018 | 20988 | 0.260 |
Why?
|
Humans | 49 | 2024 | 760740 | 0.260 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3204 | 0.250 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2009 | 361 | 0.250 |
Why?
|
Analgesics | 2 | 2021 | 1067 | 0.240 |
Why?
|
Obesity | 2 | 2024 | 12934 | 0.230 |
Why?
|
Colorectal Neoplasms | 3 | 2022 | 6927 | 0.230 |
Why?
|
Cyclohexanols | 1 | 2004 | 126 | 0.220 |
Why?
|
Serotonin Agents | 1 | 2002 | 29 | 0.210 |
Why?
|
Barrett Esophagus | 1 | 2006 | 492 | 0.200 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2011 | 1228 | 0.190 |
Why?
|
Tension-Type Headache | 1 | 2002 | 76 | 0.190 |
Why?
|
Anti-Obesity Agents | 1 | 2024 | 227 | 0.190 |
Why?
|
Atrial Fibrillation | 1 | 2019 | 5031 | 0.180 |
Why?
|
Female | 28 | 2023 | 392203 | 0.180 |
Why?
|
Androstadienes | 2 | 2016 | 348 | 0.180 |
Why?
|
Primary Health Care | 3 | 2016 | 4677 | 0.170 |
Why?
|
Middle Aged | 18 | 2023 | 220603 | 0.170 |
Why?
|
Postmenopause | 1 | 2009 | 2511 | 0.170 |
Why?
|
Mammography | 5 | 2018 | 2430 | 0.160 |
Why?
|
Risk Reduction Behavior | 2 | 2016 | 1110 | 0.160 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2004 | 574 | 0.160 |
Why?
|
Gastroesophageal Reflux | 1 | 2006 | 821 | 0.160 |
Why?
|
Panic Disorder | 1 | 2002 | 613 | 0.160 |
Why?
|
Aromatase Inhibitors | 2 | 2016 | 513 | 0.160 |
Why?
|
Tamoxifen | 2 | 2016 | 965 | 0.150 |
Why?
|
Aged | 17 | 2023 | 169092 | 0.150 |
Why?
|
Preventive Health Services | 1 | 2022 | 566 | 0.150 |
Why?
|
Lyme Disease | 1 | 2003 | 631 | 0.150 |
Why?
|
HIV Infections | 1 | 2024 | 17342 | 0.140 |
Why?
|
Colchicine | 1 | 2018 | 259 | 0.140 |
Why?
|
Diabetic Nephropathies | 1 | 2024 | 972 | 0.140 |
Why?
|
Administration, Inhalation | 1 | 2020 | 1156 | 0.140 |
Why?
|
Alendronate | 1 | 2018 | 175 | 0.140 |
Why?
|
Prostatic Neoplasms | 1 | 2019 | 11107 | 0.130 |
Why?
|
Metformin | 1 | 2024 | 906 | 0.130 |
Why?
|
Risk Factors | 7 | 2022 | 74128 | 0.130 |
Why?
|
United States | 10 | 2024 | 72292 | 0.130 |
Why?
|
Feces | 1 | 2022 | 1490 | 0.130 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2016 | 131 | 0.130 |
Why?
|
Patient Satisfaction | 2 | 2008 | 3451 | 0.130 |
Why?
|
Neuroprotective Agents | 1 | 2002 | 957 | 0.130 |
Why?
|
Pravastatin | 1 | 2017 | 392 | 0.130 |
Why?
|
Glomerular Filtration Rate | 1 | 2024 | 2174 | 0.130 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2018 | 370 | 0.120 |
Why?
|
Borderline Personality Disorder | 1 | 2003 | 768 | 0.120 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13635 | 0.120 |
Why?
|
Colonoscopy | 1 | 2023 | 1397 | 0.120 |
Why?
|
Anti-Bacterial Agents | 2 | 2023 | 7403 | 0.120 |
Why?
|
Acetaminophen | 1 | 2018 | 555 | 0.120 |
Why?
|
Hypnotics and Sedatives | 1 | 2002 | 1178 | 0.120 |
Why?
|
Evidence-Based Medicine | 2 | 2017 | 3680 | 0.120 |
Why?
|
Anti-Retroviral Agents | 1 | 2024 | 1783 | 0.120 |
Why?
|
Urology | 1 | 2019 | 400 | 0.110 |
Why?
|
Chronic Disease | 3 | 2023 | 9310 | 0.110 |
Why?
|
Prednisone | 1 | 2018 | 1562 | 0.110 |
Why?
|
Central Nervous System Stimulants | 1 | 2002 | 1177 | 0.110 |
Why?
|
Male | 14 | 2024 | 360402 | 0.110 |
Why?
|
Osteoporotic Fractures | 1 | 2018 | 410 | 0.110 |
Why?
|
Diphosphonates | 1 | 2018 | 635 | 0.110 |
Why?
|
Complementary Therapies | 1 | 2017 | 486 | 0.110 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2007 | 4010 | 0.100 |
Why?
|
Life Style | 1 | 2024 | 3907 | 0.100 |
Why?
|
Cholesterol, LDL | 1 | 2022 | 2378 | 0.100 |
Why?
|
Psychotherapy | 2 | 2017 | 1648 | 0.100 |
Why?
|
Asymptomatic Diseases | 1 | 2015 | 587 | 0.100 |
Why?
|
Hypoglycemia | 1 | 2019 | 883 | 0.100 |
Why?
|
Comparative Effectiveness Research | 1 | 2017 | 708 | 0.100 |
Why?
|
Absorptiometry, Photon | 1 | 2018 | 1738 | 0.100 |
Why?
|
Hospice Care | 3 | 2003 | 677 | 0.100 |
Why?
|
Internal Medicine | 1 | 2019 | 1051 | 0.100 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2004 | 1877 | 0.090 |
Why?
|
Antazoline | 1 | 1990 | 6 | 0.090 |
Why?
|
Naphazoline | 1 | 1990 | 7 | 0.090 |
Why?
|
Anticholesteremic Agents | 1 | 2017 | 967 | 0.090 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2017 | 1116 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4845 | 0.090 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 928 | 0.080 |
Why?
|
Quality of Life | 2 | 2018 | 13359 | 0.080 |
Why?
|
Renal Artery | 1 | 2011 | 351 | 0.080 |
Why?
|
Breast | 1 | 2018 | 1963 | 0.080 |
Why?
|
Acute Disease | 1 | 2020 | 7236 | 0.080 |
Why?
|
Conjunctivitis, Allergic | 1 | 1990 | 125 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2270 | 0.080 |
Why?
|
Physician's Role | 1 | 2015 | 917 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2011 | 491 | 0.070 |
Why?
|
Recurrence | 1 | 2018 | 8426 | 0.070 |
Why?
|
Omeprazole | 1 | 2006 | 105 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2019 | 3599 | 0.070 |
Why?
|
Cognition | 1 | 2023 | 6988 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 3805 | 0.060 |
Why?
|
Treatment Outcome | 3 | 2021 | 64572 | 0.060 |
Why?
|
Palliative Care | 1 | 2020 | 3593 | 0.060 |
Why?
|
Bone Density | 1 | 2018 | 3548 | 0.060 |
Why?
|
Esophagoscopy | 1 | 2006 | 398 | 0.060 |
Why?
|
Adult | 8 | 2024 | 220995 | 0.060 |
Why?
|
Parapsoriasis | 1 | 2003 | 2 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12966 | 0.060 |
Why?
|
Cardiology | 1 | 2015 | 1656 | 0.060 |
Why?
|
Imidazoles | 1 | 1990 | 1175 | 0.060 |
Why?
|
Carcinoma, Lobular | 1 | 2008 | 480 | 0.060 |
Why?
|
Smoking | 1 | 2020 | 9054 | 0.050 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2015 | 2020 | 0.050 |
Why?
|
Clonazepam | 1 | 2002 | 135 | 0.050 |
Why?
|
Decision Making | 1 | 2015 | 3919 | 0.050 |
Why?
|
Proton Pump Inhibitors | 1 | 2006 | 533 | 0.050 |
Why?
|
SEER Program | 5 | 2005 | 1450 | 0.050 |
Why?
|
Advance Care Planning | 1 | 2008 | 683 | 0.050 |
Why?
|
Relaxation Therapy | 1 | 2002 | 181 | 0.050 |
Why?
|
Terminally Ill | 1 | 2003 | 240 | 0.050 |
Why?
|
Hospices | 1 | 2003 | 245 | 0.040 |
Why?
|
Mastectomy, Segmental | 1 | 2005 | 955 | 0.040 |
Why?
|
Attitude to Death | 1 | 2003 | 400 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2023 | 20556 | 0.040 |
Why?
|
Anti-Anxiety Agents | 1 | 2002 | 397 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2020 | 58919 | 0.040 |
Why?
|
Treatment Refusal | 1 | 2002 | 429 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4849 | 0.040 |
Why?
|
Risk | 2 | 2007 | 9603 | 0.040 |
Why?
|
Physical Examination | 1 | 2004 | 1254 | 0.040 |
Why?
|
Fee-for-Service Plans | 1 | 2003 | 697 | 0.040 |
Why?
|
Managed Care Programs | 1 | 2003 | 937 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2002 | 6305 | 0.040 |
Why?
|
Psychotropic Drugs | 1 | 2003 | 888 | 0.040 |
Why?
|
Behavior Therapy | 1 | 2003 | 877 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 3705 | 0.030 |
Why?
|
Health Surveys | 1 | 2004 | 4036 | 0.030 |
Why?
|
Depression | 2 | 2003 | 8132 | 0.030 |
Why?
|
Medicare | 3 | 2003 | 6774 | 0.020 |
Why?
|
Neoplasm Staging | 2 | 2005 | 11118 | 0.020 |
Why?
|
Hyperemia | 1 | 1990 | 221 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2003 | 13383 | 0.020 |
Why?
|
Advance Directives | 1 | 2008 | 249 | 0.020 |
Why?
|
Conjunctiva | 1 | 1990 | 479 | 0.020 |
Why?
|
Regression Analysis | 2 | 2006 | 6339 | 0.020 |
Why?
|
Neoplasms | 2 | 2003 | 22131 | 0.010 |
Why?
|
Drug Combinations | 1 | 1990 | 2048 | 0.010 |
Why?
|
Pacific Islands | 1 | 2003 | 52 | 0.010 |
Why?
|
Asia | 1 | 2005 | 616 | 0.010 |
Why?
|
Hospitalization | 1 | 2003 | 10708 | 0.010 |
Why?
|
Allergens | 1 | 1990 | 1429 | 0.010 |
Why?
|
Georgia | 1 | 2000 | 183 | 0.010 |
Why?
|
Connecticut | 1 | 2000 | 364 | 0.010 |
Why?
|
Insurance Claim Reporting | 1 | 2000 | 165 | 0.010 |
Why?
|
Washington | 1 | 2000 | 315 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2008 | 3514 | 0.010 |
Why?
|
Age Distribution | 1 | 2005 | 2872 | 0.010 |
Why?
|
Length of Stay | 2 | 2003 | 6418 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2008 | 2419 | 0.010 |
Why?
|
Medical Record Linkage | 1 | 2000 | 286 | 0.010 |
Why?
|
Proportional Hazards Models | 2 | 2003 | 12448 | 0.010 |
Why?
|
Retrospective Studies | 5 | 2003 | 80583 | 0.010 |
Why?
|
Terminal Care | 1 | 2008 | 1755 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2005 | 8516 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2006 | 12043 | 0.010 |
Why?
|
Insurance, Health | 1 | 2003 | 2495 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3683 | 0.010 |
Why?
|
Logistic Models | 1 | 2003 | 13248 | 0.000 |
Why?
|
Survival Analysis | 1 | 2000 | 10072 | 0.000 |
Why?
|
Registries | 1 | 2003 | 8209 | 0.000 |
Why?
|
Age Factors | 1 | 2003 | 18381 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2006 | 26065 | 0.000 |
Why?
|
Time Factors | 1 | 2003 | 39908 | 0.000 |
Why?
|
Cohort Studies | 1 | 2000 | 41464 | 0.000 |
Why?
|
Concepts
(207)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(45)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_